Based in Montreal, CTI Life Sciences Fund L.P. is a limited partnership formed in 2006. The Fund make venture capital investments in high quality emerging life sciences companies at the start-up and clinical development stage primarily in Canada. This fund is the first of its kind created in Quebec since 2002.

CTI Life Sciences Fund L.P. has secured C$100 million in commitments from Quebec, institutional investors such as the Caisse de dépôt et placement du Québec, the Solidarity Fund QFL, FIER Partners L.P. and the Régime de rentes du Mouvement Desjardins and CTI Capital Group’s partners.

The CTI Life Sciences Fund L.P. team of professionals in science and finance has extensive experience in the biotechnology and the pharmaceutical industries. The Fund works closely with entrepreneurs and researchers to increase the value of these young companies.

Press releases

December 2nd 2013 - Xagenic Inc. Completes $20 Million Series B Financing

July 12th 2013 - Medicago announces agreement to be acquired by Mitsubishi Tanabe Pharma in a transaction valued at $357M

October 5th 2012 - Fonds de solidarité FTQ, CTI Life Sciences Fund and Ferring Pharmaceuticals Create a New Biotech in Québec

February 10th 2012 - Closing of acquisition of Enobia by Alexion - Yet another successful portfolio exit for CTI's Life Sciences Fund

Janvier 30th 2012 - Xagenic Inc. Closes $10 Million Series A Financing with CTI Life Sciences Fund, Ontario Emerging Technologies Fund (OETF) and QIAGEN N.V..

December 28th 2011 - Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)

September 27th 2011 - Medicago Completes $25 Million Private Placement.

August 29th 2011 - Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies.

August 8th 2011 - Enobia Pharma Raises US $40 million.

April 5th 2011 - Medicago Announces Closing of $17.4 Million Equity Offering.

June 30th 2010 - Sanofi-aventis to acquire TargeGen Inc., a US biopharmaceutical company.

June 29th 2010 - Zymeworks Closes C$3.2M Round of Financing

February 11th 2010 - Somnus Therapeutics Closes US$15 Million Series A Financing with CTI Life Sciences and Care Capital

December 29th 2009 - NeurAxon Announces Closing of Convertible Debenture Financing

August 10th 2009 - Enobia Raises US$50M from Current Investors in Series C Financing

June 23rd 2009 - Zymeworks Closes C$3.4 million Financing Round and Announces Changes to its Board of Directors

October 15th 2007 - Chlorion Pharma Inc. Closes C$6.0 million Financing Round

September 11th 2007 - Enobia Pharma Inc. Closes C$40.1 million Series B Financing Round

July 12th 2007 - TargeGen Inc. Closes $40.0M Series D Financing Round

© CTI Life Sciences Fund L.P. All rights reserved.
“Where broad operational and venture capital experience come together to create and realize shareholder value in Life Sciences Companies with pre-clinical and clinical stage drugs and enabling technologies.”